Validating cancer drug targets. - Wikidata - wikimedia - TriplyDB

Validating cancer drug targets.

Validating cancer drug targets.

http://www.wikidata.org/entity/Q36488747

about

Using multiple microenvironments to find similar ligand-binding sites: application to kinase inhibitor binding Impact of image segmentation on high-content screening data quality for SK-BR-3 cells Proteomic identification of secreted proteins as surrogate markers for signal transduction inhibitor activity Human anti-gold antibodies: biofunctionalization of gold nanoparticles and surfaces with anti-gold antibodies.Methodological approaches in application of synthetic lethality screening towards anticancer therapy Cytotoxic Activities of Physalis minima L. Chloroform Extract on Human Lung Adenocarcinoma NCI-H23 Cell Lines by Induction of Apoptosis.Targeting the EGF receptor for ovarian cancer therapy.Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2 Gene profiling of MTA1 identifies novel gene targets and functions.Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway.Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity.Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas.Functional interrogation of breast cancer: from models to drugs.Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward?A high-throughput screen with isogenic PTEN+/+ and PTEN-/- cells identifies CID1340132 as a novel compound that induces apoptosis in PTEN and PIK3CA mutant human cancer cells VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies.CD200: association with cancer stem cell features and response to chemoradiation in head and neck squamous cell carcinoma.Tissue-specific and reversible RNA interference in transgenic mice.Inducible and reversible regulation of endogenous gene in mouse Back to the future: mechanism-based, mutation-specific combination chemoprevention with a synthetic lethality approach.New approaches to molecular cancer therapeutics.Modeling, simulation, and translation framework for the preclinical development of monoclonal antibodies Inducible and reversible gene silencing by stable integration of an shRNA-encoding lentivirus in transgenic rats.High-throughput kinase profiling as a platform for drug discovery.Target validation to biomarker development: focus on RNA interference.LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer.Chemobehavioural phenomics and behaviour-based psychiatric drug discovery in the zebrafish Systemic Inhibition of CREB is Well-tolerated in vivo.Genomic approaches to small molecule discovery.The Translational Research Working Group developmental pathway for anticancer agents (drugs or biologics).Ubiquitin-specific proteases as cancer drug targets.Discovery of small molecule cancer drugs: successes, challenges and opportunities.At the frontier of progress for paediatric oncology: the neuroblastoma paradigm.One-step Conjugation of Glycyrrhetinic Acid to Cationic Polymers for High-performance Gene Delivery to Cultured Liver Cell.Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Euro Intracellular microenvironment-responsive label-free autofluorescent nanogels for traceable gene delivery.Phosphorylation: Implications in Cancer.Development of a Grp94 inhibitor.

P2860

Q28478631-95DCC94D-5B98-40B9-B52B-0E70388A9F07 Q31128961-22AAAA3E-FC5E-45A1-B1C4-660974F2DE23 Q33268625-805D428F-0995-4125-817F-675EDEB20EE2 Q33379776-3534F63A-10AA-49FD-B4DA-788430674D2F Q33421697-8E25BE4E-2BB0-4C68-BC4F-69836E8218BA Q33471086-3AE1AE4D-3DD3-4189-8916-EB6951E6EBEC Q33570526-EA03A7C7-8640-41E2-84C8-19582E5D211D Q33686871-434C709E-C3A0-42E2-8E59-71CED83789C4 Q33833747-56B9D818-8C64-4F1C-9992-968DBF712762 Q33852403-B4E121F4-6671-4946-BD99-D62E3CDB2471 Q33866783-E436545B-BFD8-466B-8CBF-F85FC01F6C74 Q33971120-F9F55148-98BC-4652-A497-88B06EE63267 Q34498746-C4826475-A2B7-40EA-8888-9CC34B83C529 Q34626308-F0223501-66AB-409A-B19D-D7EEE4C37258 Q34847802-9E8BE858-DBA0-4731-81D6-7BB2AA54E7BC Q35238017-0934D666-1D2A-4864-8F8C-B6811199E2C4 Q35585704-7C36C202-142E-4C1E-A083-4A82C79C529C Q35859128-41D93F4C-5F1B-4659-BEC5-2995F6A0E8C3 Q36019782-B98D1C9F-81BB-458B-9BED-DF39B40596CE Q36129232-06F14AEC-B880-4B23-AAFF-60C61AF5BCA8 Q36422264-CD4AE43D-4031-470F-9BC7-624E5C554B8A Q36616621-2AB8B375-4871-4749-850B-9746535DA9E4 Q36654909-0CE10DE6-B3E2-4346-BA61-349FA1E70E6D Q36910611-91BF4CFD-5212-43C1-A0D8-D56AF67E40E2 Q36985023-A3A720CE-5A29-42A9-83BF-BD3A7C8A2993 Q37135359-A035F016-A258-42D1-9DB0-C0C8724B1415 Q37141990-9CA5BA00-394C-4D16-9DC4-08F8507586E2 Q37165231-70B6B23D-9F97-47F2-AEB8-6AEBFCA2E61B Q37265890-DA1843CE-ED51-40DD-8416-0093A1CE287E Q37303415-A77E50E7-2BA1-42D2-9974-12B7C67933FD Q37406963-B1EB97B9-4BE6-490D-8893-294FFC30E021 Q37689252-18D98D6E-7738-450F-8341-CF090F4D6551 Q37875076-0A084269-5DD0-4FED-9651-250FBF554433 Q37996113-E27014DF-3732-494D-98E9-AD4E16779DB1 Q38161274-F314AA5D-D235-4797-9F11-2AA539CF5202 Q38593380-A95E76A9-D0D8-4CDD-AF89-47FA4A41C2FC Q38730798-475D2AA2-CF2F-4511-9A36-2529350A0109 Q38981256-1A9C54F8-C69A-4B3E-BC38-CA0F77FAB2E8 Q39097149-921041A4-5132-439E-B5B0-6DA17E50F82B Q39340802-D56249F5-7F5B-464C-AC0D-22C631507D30

P2860

Validating cancer drug targets.

http://www.wikidata.org/entity/Q36488747

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Validating cancer drug targets.

@ast

Validating cancer drug targets.

@en

type

label

Validating cancer drug targets.

@ast

Validating cancer drug targets.

@en

prefLabel

Validating cancer drug targets.

@ast

Validating cancer drug targets.

@en

P1433

Q36488747-85BC2B74-2D15-4427-95DB-3DB5915CC2D0

P1476

Q36488747-C7A3FDA6-EF46-4F16-9B4E-743E205948D3

P2093

Q36488747-149E9E70-C296-4AFB-A742-903B1226F681

Q36488747-25E1C177-D17C-42CF-8B83-A164AD74211D

Q36488747-2A555CB2-845F-4C2A-974E-838BC25BD665

Q36488747-34F8ED5C-3E55-4FFB-B327-D2A7D0373176

Q36488747-3E5CB963-3A26-41BA-B9B2-713CC313AAEC

Q36488747-675073FB-F89A-4D71-A588-457EEB9EE586

Q36488747-7776ADF6-6B31-49A2-BDF0-E066BDBDD1CD

Q36488747-93956103-47C4-46A9-82F3-7C474ACFC26A

P2860

Q36488747-015CCBBC-8638-4477-8412-C8EB0505D9FD

Q36488747-0C1BCAF8-EE0D-457C-BC7C-27CAA673C212

Q36488747-123ED220-0EBD-4739-BEF5-B4C6DCF5AEE4

Q36488747-21638C5B-7F8F-4D96-AA46-CA08B72CAFC6

Q36488747-2197009B-4D35-449D-A70B-60FB02D5972F

Q36488747-29AC0E17-1504-454C-9BE5-98594892E9D3

Q36488747-32A2E65C-D12D-4086-8DAB-608FBECDE98B

Q36488747-36E98342-387D-41DD-8686-8ED92DB53629

Q36488747-386C20CE-0634-485D-822F-D6C9520916C2

Q36488747-3D70F629-0E8C-4C52-B9E7-6370349E22FB

P2888

Q36488747-37777698-3B64-4A29-8D55-5A788F1CF670

P304

Q36488747-B0CC959F-18E0-4976-AE91-DAE49F3228C5

P31

Q36488747-D1ACA3FF-112F-4FD6-A96C-D1C811FFB447

P356

Q36488747-031385F7-E726-4E31-ADAE-D91055589DD3

P407

Q36488747-FA5C76F1-1F79-49D7-A324-0DB688CAD3C3

P433

Q36488747-9DD585AF-B197-4E56-AEA3-2562CB3EAC1E

P478

Q36488747-CFBD36A5-A5BE-4500-9964-C34B8D9D2580

P577

Q36488747-8DA03D5D-0F0D-49AD-9B98-433B68EDC7DE

P5875

Q36488747-36CAE5E3-DD24-42AB-9251-EBDC883E7900

P6179

Q36488747-1DE3870A-5C3F-459B-B5A7-D0248EB8A0FC

P698

Q36488747-646596C2-3CCF-4A97-AFF4-D38B2B362996

P356

P1433

P1476

Validating cancer drug targets.

@en

P2093

Christoph Lengauer

http://www.w3.org/2001/XMLSchema#string

John D Benson

http://www.w3.org/2001/XMLSchema#string

Magdalena Leszczyniecka

http://www.w3.org/2001/XMLSchema#string

Marion Dorsch

http://www.w3.org/2001/XMLSchema#string

Sunkyu Kim

http://www.w3.org/2001/XMLSchema#string

Susan A Cornell-Kennon

http://www.w3.org/2001/XMLSchema#string

William R Sellers

http://www.w3.org/2001/XMLSchema#string

Ying-Nan P Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Facile methods for generating human somatic cell gene knockouts using recombinant adeno-associated viruses

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Mutations of the BRAF gene in human cancer

High frequency of mutations of the PIK3CA gene in human cancers

Isolation of a transforming sequence from a human bladder carcinoma cell line

The concept of synthetic lethality in the context of anticancer therapy

Cancer. Addiction to oncogenes--the Achilles heal of cancer

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

P2888

P304

451-456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE04873

http://www.w3.org/2001/XMLSchema#string

P407

P433

7092

http://www.w3.org/2001/XMLSchema#string

P478

441

http://www.w3.org/2001/XMLSchema#string

P577

2006-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7058928

http://www.w3.org/2001/XMLSchema#string

P6179

1040010450

http://www.w3.org/2001/XMLSchema#string

P698

16724057

http://www.w3.org/2001/XMLSchema#string